View Older Stories View More Recent Stories

Nov 9, 2022 08:30AM Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
Nov 9, 2022 08:30AM Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
Nov 3, 2022 09:04AM Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
Nov 3, 2022 09:04AM Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
Nov 2, 2022 04:02PM Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Nov 2, 2022 04:02PM Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
Oct 31, 2022 08:30AM Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
Oct 31, 2022 08:30AM Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
Oct 26, 2022 08:30AM Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Oct 26, 2022 08:30AM Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Oct 11, 2022 08:30AM Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-
Oct 11, 2022 08:30AM Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-
Oct 6, 2022 04:25PM Allogene Therapeutics (ALLO) Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Oct 6, 2022 04:15PM Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Oct 6, 2022 04:15PM Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
Sep 23, 2022 08:30AM Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
Sep 23, 2022 08:30AM Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
Aug 9, 2022 04:02PM Allogene Therapeutics Reports Second Quarter 2022 Financial Results
Aug 9, 2022 04:02PM Allogene Therapeutics Reports Second Quarter 2022 Financial Results
Aug 3, 2022 08:30AM Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Aug 3, 2022 08:30AM Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Jul 27, 2022 08:30AM Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Jul 27, 2022 08:30AM Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Jul 12, 2022 08:31AM Allogene Therapeutics (ALLO) Appoints Stephen Mayo to its Board
Jul 12, 2022 08:30AM Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
Jul 12, 2022 08:30AM Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
Jun 8, 2022 08:30AM Allogene Therapeutics (ALLO) Announces the FDA Granted RMAT Designation to ALLO-501A for Large B Cell Lymphoma
Jun 8, 2022 08:30AM Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Jun 8, 2022 08:30AM Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
May 19, 2022 08:30AM Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (A
May 19, 2022 08:30AM Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (A
May 9, 2022 08:30AM Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
May 9, 2022 08:30AM Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
May 4, 2022 04:02PM Allogene Therapeutics Reports First Quarter 2022 Financial Results
May 4, 2022 04:02PM Allogene Therapeutics Reports First Quarter 2022 Financial Results
Apr 28, 2022 08:30AM Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Apr 28, 2022 08:30AM Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
Apr 27, 2022 08:30AM Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
Apr 27, 2022 08:30AM Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
Apr 27, 2022 08:01AM Allogene Therapeutics (ALLO) Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Apr 27, 2022 08:00AM Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Apr 27, 2022 08:00AM Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
Apr 14, 2022 08:00AM Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Apr 14, 2022 08:00AM Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
Apr 13, 2022 09:00AM Allogene Therapeutics (ALLO) Reports Publication of Preclinical Data on ALLO-316
Apr 13, 2022 09:00AM Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Jour
Apr 13, 2022 09:00AM Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Jour
Apr 12, 2022 08:30AM Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
Apr 12, 2022 08:30AM Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
Mar 23, 2022 08:32AM Allogene Therapeutics (ALLO) Reports Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
View More Recent Stories View Older Stories